Valeant Pharmaceuticals Intl Inc.: 3 Things to Look for as it Reports 4th-Quarter Numbers

After two delays, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will finally report fourth-quarter results on Tuesday.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is set to report its fourth-quarter results on Tuesday morning. The event has been widely anticipated, partly because it has been delayed twice already.

We’ll look at three key aspects of the call below.

1. A Philidor update

On February 22, Valeant announced that its ad hoc committee had made “substantial progress in its review of Philidor and related accounting matters.” According to the press release, Valeant had improperly recognized US$58 million of revenue in the second half of 2014.

Surprisingly, investors shrugged off the news. But as Valeant releases fourth-quarter results, we’ll all be expecting more updates from the ad hoc committee.

After all, we still don’t know for sure if there were other accounting issues surrounding Philidor. We still don’t know exactly how involved Valeant was in Philidor’s operations. And we’re not sure exactly how the SEC’s investigation–which apparently focuses on Valeant’s Philidor relationship–will play out. We don’t even know the timeline of the ad hoc committee’s investigation. Any updates would be more than welcome.

2. Guidance for 2016

On February 28, Valeant announced that Michael Pearson would be returning to his post as CEO, which most analysts would say is good news. However, the company also pulled its 2016 guidance, which set off some serious alarm bells in the analyst community.

Making matters worse, Valeant has sent mixed messages about the importance of drug pricing to its bottom line. Back in April, CEO Michael Pearson said that “volume was greater than price in terms of our growth.” But an internal email from Howard Schiller, Valeant’s CFO at the time, said that price represented about 80% of the company’s growth. We have since seen the company admit publicly that price has been more of a factor.

The price vs. volume dynamic is critical because Valeant is under intense scrutiny over its drug pricing practices. So even if there is no new drug pricing legislation, you should expect to see a brake on price hikes. We’ll see what impact that has on 2016 guidance.

3. Debt reduction and a new strategy

Thanks to its acquisitive history, Valeant has roughly US$31 billion in debt and had plans to cut it by US$2.3 billion. But with guidance suspended, the debt level becomes that much more of a concern.

To help illustrate this point, Moody’s Investors Service cut Valeant’s debt rating the same day that the company’s guidance was withdrawn. And analyst David Maris of Wells Fargo has claimed that Valeant’s debt load will consume all the company’s discretionary cash flow for the foreseeable future.

So we’ll have to see what kind of debt-reduction goals Valeant has in the upcoming year and how it plans to achieve its target. Asset sales could easily be part of the mix.

One way or another, investors are in for a wild ride.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals and Wells Fargo and has the following options: short May 2016 $52 puts on Wells Fargo.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »